Mikhail Blagosklonny’s Contribution To Oncology

Cancer is a broad field. One needs to spend many years of study to master just a segment of the same. Mikhail Blagoslonny specializes in researching about Aging and Anti-Cancer drugs. The scientist is an Oncology professor at the esteemed Roswell Park Cancer Institute. Here, he is has conducted numerous researches that have helped in expanding human’s understanding of cancer.

Mikhail has a sound educational background. He started to study medicine at the First Pavlov State Medical University where he received his MD in Internal Medicine. His passion for gaining more knowledge saw him re-enroll in the same university to pursue his PhD in Experimental Medicine and Cardiology.

Upon graduating, the young PhD holder joined New York Medical College as the college’s associate professor of medicine. The medical college is located in Valhalla, New York. After a couple of years, he stopped teaching and joined the Ordway Research Institute. Here, he served as a senior scientist until 2009. Read more on Impact Journals.

Mikhail’s experience in research intrigued Roswell Park Center Institute. Later, they entered into an agreement with him to join the research center as a Professor of Oncology. In this institution, the scientist focused his energies on cancer, targeted cancer therapies, biogerontology, and anti-aging drugs. His research also covers cell cycle, mitosis, anti-cancer therapeutics, apoptosis, tumor suppressors, and signal transduction.

Besides researching, Blagosklonny is also one of the two editors-in-chief of Oncotarget, a renowned oncology journal. He also works for Cell Cycle as an editor-in-chief. Mikhail Blagosklonny is a committed member of Cell Death and Differentiation’s editorial board. He is an associate editor of a widely read journal, Cancer Biology and Therapy. Moreover, Mikhail is an author with loads of scientific papers under his name. These papers have been peer-reviewed and published in many journals, including Oncotarget.

The researcher is also known for his hypothesis on TOR signaling and aging. He believes that TOR signaling causes both cancer and aging. To this end, he is optimistic that anti-cancer drugs such as Rapamycin can be used for life longevity. Although the studies on this claim are in their early stages, preliminary results indicate that his hypothesis might be right. Check Mikhail’s profile in LinkedIn